Amgen (NASDAQ:AMGN) Stock Sale Revealed by Rep. David Taylor

Representative David Taylor (Republican-Ohio) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on November 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Amgen stock on November 3rd. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 11/5/2026.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 11/5/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 11/5/2026.
• Purchased $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 11/5/2026.
• Sold $1,001 – $15,000 in shares of Eli Lilly and Company (NYSE:LLY) on 11/3/2026.
• Purchased $1,001 – $15,000 in shares of Eaton (NYSE:ETN) on 11/3/2026.
• Sold $1,001 – $15,000 in shares of Kroger (NYSE:KR) on 11/3/2026.
• Purchased $1,001 – $15,000 in shares of AT&T (NYSE:T) on 11/3/2026.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/3/2026.
• Sold $1,001 – $15,000 in shares of Visa (NYSE:V) on 11/3/2026.

Amgen Price Performance

NASDAQ AMGN traded down $1.39 during trading hours on Friday, reaching $465.67. 2,122,101 shares of the stock traded hands, compared to its average volume of 2,720,013. The stock has a 50 day simple moving average of $425.31 and a two-hundred day simple moving average of $381.17. Amgen Inc. has a 1 year low of $312.39 and a 1 year high of $483.99. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. The company has a market cap of $251.89 billion, a price-to-earnings ratio of 27.01, a price-to-earnings-growth ratio of 3.25 and a beta of 0.43.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The company had revenue of $10.37 billion for the quarter, compared to analysts’ expectations of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. Amgen’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period last year, the firm posted $5.64 EPS. On average, analysts predict that Amgen Inc. will post 23.37 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, November 20th. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. Amgen’s dividend payout ratio (DPR) is 58.47%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Quest 10 Wealth Builders Inc. raised its holdings in Amgen by 220.0% in the 3rd quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock worth $34,000 after acquiring an additional 55 shares during the last quarter. Wellington Altus USA Inc. boosted its stake in Amgen by 72.3% during the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 34 shares during the last quarter. Nvwm LLC boosted its stake in Amgen by 412.5% during the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 66 shares during the last quarter. PFS Partners LLC increased its holdings in shares of Amgen by 95.5% in the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock worth $36,000 after purchasing an additional 42 shares in the last quarter. Finally, TOWER TRUST & INVESTMENT Co bought a new stake in shares of Amgen in the 3rd quarter worth $38,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on AMGN. William Blair reiterated an “outperform” rating on shares of Amgen in a report on Wednesday, November 4th. The Goldman Sachs Group increased their target price on Amgen from $481.00 to $536.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Royal Bank Of Canada raised their target price on Amgen from $430.00 to $470.00 and gave the company an “outperform” rating in a research note on Wednesday, November 4th. Piper Sandler lifted their price target on Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. Finally, Argus upped their target price on shares of Amgen from $460.00 to $515.00 and gave the stock a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $424.66.

Trending Headlines about Amgen

These are some of the AMGN headlines that stood out recently:

• Positive Sentiment: Amgen said dazodalibep met key endpoints in a Phase 3 Sjögren’s disease trial, advancing the case for the drug as a potential future growth driver. Jefferies analysts said caveated comparisons suggest its efficacy may look stronger than Novartis’ registrational treatment. Article Article
• Positive Sentiment: Argus raised its price target to $515 from $460 and maintained a buy rating, signaling further upside in its view. Article
• Neutral Sentiment: A comparison of Amgen and Vertex highlights Amgen’s broad global footprint and diversified medicines portfolio, but offers no clear near-term catalyst for the shares. Article

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Amgen Company Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.